allergic rhinitis
Conditions
Interventions
Sponsors
The Teaching Hospital of Chengdu University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Those who meet the above diagnostic standards; 2. Patients with a positive skin prick test of grade 2 or above; 3. Aged 18 to 65 years without gender restriction; 4. Not received any medication for AR in the past two weeks; 5. Agree to participate in this test and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients combined with severe nasal septal deviation, chronic nasal-sinusitis, bronchial asthma, nasal polyps and other diseases; 2. With heart, liver and kidney disorder or autoimmune diseases; 3. combined with mental illness, mental disorders and unable to cooperate to complete the test; 4. Patients during pregnancy, lactation, or during pregnancy preparation; 5. Patient is allergic to the composition of the clinical trial drug; 6. Patients who had received glucocorticoids, leukotriene receptor blockers, antihistamines, or anti-inflammatory drugs within two weeks; 7. Patients with skin pathological changes at the site of the skin prick test; 8. Patients who are currently and have previously participated in specific immunotherapy; 9. Patients who have participated in other clinical studies in the past two months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| six-month recurrence rate of AR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of medication (days);Visual analog scale;Rhinoconjunctivitis quality of life scale;Total score for nasal symptoms;Total score for eye symptoms;Chinese Medicine Physique Classification and Judgment Table;Spleen Qi Deficiency Systemic Symptoms Scoring Table;Lung Qi Deficiency Systemic Symptoms Scoring Table;Carbon monoxide;Platelet activating factor;Toll-like receptor 4;Human chemokine receptor 6;Human chemokine receptor 7;Heme oxygenase 1;Myeloid differentiation factor;TIR domain adaptor protein;Interleukin 4;Interferon gamma;Tumor Necrosis Factor Alpha;Nuclear factor-??;Nasal endoscopic results;Rhinitis Control Assessment Test (RCAT);one-month recurrence rate of AR;the duration of follow-up (days); | — |
Countries
China
Contacts
Public ContactTian Li
The Teaching Hospital of Chengdu University of Traditional Chinese Medicine
Outcome results
None listed